SC dismissed appeal for classification of ‘Kadiprol’ as drug & medicine

  • Blog|News|GST & Customs|
  • < 1 minute
  • By Taxmann
  • |
  • Last Updated on 14 July, 2022

Recent Posts

Blog, News, Insolvency and Bankruptcy Code

Interim Moratorium Barred Continuation of Proceedings u/s 138 of NI Act Against Petitioner Due to IBC’s Overriding Effect | HC

Blog, News, FEMA & Banking

Borrower’s Right to Redeem Secured Asset Ends on Publication of Notice u/s 9(1) of SI Rules, Not After Sale Completion | SC

Latest from Taxmann

Medicine; Kadiprol

Case Details: State of Gujarat V. Cadila healthcare ltd. - [2022] 140 taxmann.com 254 (SC)

Judiciary and Counsel Details

    • M.R. Shah & Sanjiv Khanna, JJ.

Facts of the Case

The issue pertains to the classification of ‘Kadiprol’ under the Gujarat Sales Tax Act that whether the same should be classified as ‘poultry feed’ under Entry 25 of Schedule I or ‘drug and medicine’ under Entry 26(1) of Schedule II Part A. The assessee classified the product as poultry feed whereas the Department was of the view that it should be classified as drug and medicine.

The matter reached to the Gujarat High Court where it was held that Kadiprol would be classified as poultry feed. The State of Gujarat then filed an appeal before the Supreme Court.

Supreme Court Held

The Hon’ble Supreme Court dismissed the case on the basis that the judgment passed by the Gujarat High Court lacks a detailed and in-depth examination of facts. The Supreme Court decided not to remand back the matter to the High Court for a fresh decision due to lack of revenue implication. Though, the Supreme Court categorically commented that the question of classification would be kept open and the matter may be considered in an appropriate case by applying the common parlance test.

Disclaimer: The content/information published on the website is only for general information of the user and shall not be construed as legal advice. While the Taxmann has exercised reasonable efforts to ensure the veracity of information/content published, Taxmann shall be under no liability in any manner whatsoever for incorrect information, if any.

Leave a Reply

Your email address will not be published. Required fields are marked *

«
»

Everything on Tax and Corporate Laws of India

To subscribe to our weekly newsletter please log in/register on Taxmann.com

Author: Taxmann

Taxmann Publications has a dedicated in-house Research & Editorial Team. This team consists of a team of Chartered Accountants, Company Secretaries, and Lawyers. This team works under the guidance and supervision of editor-in-chief Mr Rakesh Bhargava.

The Research and Editorial Team is responsible for developing reliable and accurate content for the readers. The team follows the six-sigma approach to achieve the benchmark of zero error in its publications and research platforms. The team ensures that the following publication guidelines are thoroughly followed while developing the content:

  • The statutory material is obtained only from the authorized and reliable sources
  • All the latest developments in the judicial and legislative fields are covered
  • Prepare the analytical write-ups on current, controversial, and important issues to help the readers to understand the concept and its implications
  • Every content published by Taxmann is complete, accurate and lucid
  • All evidence-based statements are supported with proper reference to Section, Circular No., Notification No. or citations
  • The golden rules of grammar, style and consistency are thoroughly followed
  • Font and size that's easy to read and remain consistent across all imprint and digital publications are applied